Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Travoprost Ophthalmic Solution".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Travoprost Ophthalmic Solution".